Results 121 to 130 of about 143,948 (293)

The ABO blood groups of carcinoma of the oesophagus and of benign prostatic hyperplasia [PDF]

, 1964
Will Beasley
openalex   +1 more source

What spatial omics is teaching us about field cancerisation in prostate and bladder cancer

BJU International, EarlyView.
Background and Objectives Field cancerisation is the process that results in a group of cells acquiring some of the phenotypic changes of cancer prior to transformation into cancer. Clinically, an important challenge remains the ability to distinguish clonal lineages and microenvironments within cancerised fields that will remain indolent from those ...
Matthew H. V. Byrne, Thineskrishna Anbarasan, Lisa Browning, Dan J. Woodcock   +3 more
wiley   +1 more source

Rescoring the NIH chronic prostatitis symptom index: nothing new. [PDF]

, 2009
The National Institutes of Health-chronic prostatitis symptom index (NIH-CPSI) is a commonly used 13-item questionnaire for the assessment of symptom severity in men with chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS).
Calhoun, EA, Clemens, JQ, Crowley, EM, Dunn, RL, Landis, JR, Litwin, MS, McNaughton-Collins, M   +6 more
core  

Benign prostatic hyperplasia and periodontitis [PDF]

Yixue xinzhi zazhi
Benign prostatic hyperplasia and periodontitis are common chronic diseases in middle-aged and elderly people, with many common risk factors and pathogenesis.
YANG Shisong, ZHU Cong, QIAN Xinhang, HOU Junqing, FANG Cheng   +4 more
doaj   +1 more source

Basal cell proliferation in benign prostatic hyperplasia [PDF]

, 1978
Gerald B. Dermer
openalex   +1 more source

Targeting ROCK1/YAP1 Axis Ameliorates Inflammation‐Induced Prostatic Hyperplasia via Stabilising SIRT1‐Dependent Mitochondrial Dynamics

Cell Proliferation, EarlyView.
Prostate‐specific YAP1 overexpression induces pathological BPH phenogenesis. Targeting ROCK1/YAP1 with fasudil and verteporfin alleviates inflammatory BPH lesions. YAP1 orchestrates mitochondrial dysfunction and oxidative stress via suppressing SIRT1 function.
Dongxu Lin, Pengyu Wei, Mengyang Zhang, Kang Li, Lina Li, Zhipeng Li, Changcheng Luo, Wenbo Kuang, Kai Cui, Zhong Chen   +9 more
wiley   +1 more source

Holmium Laser Enucleation Versus Transurethral Resection in Patients with Benign Prostatic Hyperplasia

Central Asian Journal of Medical Sciences, 2017
Objectives: To evaluate efficacy and safety of the holmium laser enucleation of the prostate (HoLEP) compared to transurethral resection of the prostate (TURP) for treatment of benign prostatic hyperplasia.
Liu Suo, Munkhbayarlakh Sonomjamts, Sergelen Orgoi, Shiirevnyamba Avirmed   +3 more
doaj   +1 more source

Urinary cholesterol excretion in men with benign prostatic hyperplasia and carcinoma of the prostate [PDF]

, 1979
Dieter Juengst, Angelika Pickel, E Elsaesser, Franz J. Marx, Hans Josef Karl   +4 more
openalex   +1 more source

Management of Benign Prostatic Hyperplasia.

Annual Review of Medicine, 2016
Benign prostatic hyperplasia (BPH) and associated lower urinary tract symptoms (LUTS) commonly affect older men. Age-related changes associated with metabolic disturbances, changes in hormone balance, and chronic inflammation may cause BPH development ...
Eric H. Kim, J. Larson, G. Andriole
semanticscholar   +1 more source

Recombinant Activated Factor VIIa Combined With Tranexamic Acid Control Haemostasis in Patients With Severe Factor XI Deficiency Undergoing Urological Procedures

Haemophilia, EarlyView.
ABSTRACT Introduction Patients with severe Factor XI deficiency face unique challenges during urological procedures due to an elevated risk of bleeding, balanced against the use of tranexamic acid (TXA), which may form blood clots. Given the limitations associated with plasma‐based treatment, there have been reports of successful and safe off‐label use
Neta Sternbach, Yaron Ehrlich, Anfisa Stenevsky, Daniel Saidian, Darawsha Abd Elhalim, Jack Baniel, Pia Raanani, Galia Spectre   +7 more
wiley   +1 more source